Piramal Pharma balance sheet

As of Sep 2026

Total assets: ₹18,537cr+14.5% on Sep 2025
Shareholders' equity: ₹8,165cr+1.1% on Sep 2025
Total debt: ₹5,665cr+20.1% on Sep 2025
Cash and investments: ₹806cr+11.7% on Sep 2025

₹ crore except per share

Tap a line for its trend	H1 FY27Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Current assets
Non-current assets						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	4,496	4,451	4,176	3,873	3,363
	966	799	489	566	853
	1,405	1,257	1,148	1,123	1,108
	2,848	2,584	2,451	2,617	2,773
	306	301	488	550	566
	110	244	227	205	170
	62.7	60.8	44.3	34.9	41.8
	52.0	40.3	20.7	20.8	247
	115	101	65.0	55.8	289
	494	515	393	387	349
	544	522	444	472	217
	11,284	10,773	9,881	9,847	9,687
	3,295	3,064	2,313	2,176	1,681
	261	132	19.6	145	427
	2,254	2,158	2,350	2,134	1,799
	545	1,200	369	357	196
	23.6	23.8	132	126	112
	60.1	65.5	55.6	15.9	92.4
	3,144	3,579	2,926	2,778	2,626
	815	549	552	511	528
	7,254	7,192	5,797	5,464	4,835
	18,537	17,965	15,678	15,312	14,523
Equity
	1,328	1,327	1,324	1,323	1,193
	6,814	6,835	6,801	6,588	5,580
	8,142	8,163	8,125	7,911	6,774
	22.5	0.0	0.0	—	—
	8,165	8,163	8,125	7,911	6,774
Liabilities
	4,454	4,300	3,214	2,484	3,384
	160	135	99.2	118	107
	4,614	4,435	3,313	2,602	3,490
	117	94.3	48.7	32.3	20.7
	351	358	248	229	219
	132	156	176	168	176
	5,214	5,044	3,786	3,031	3,906
	1,212	1,196	1,506	2,075	2,121
	2,735	2,479	1,534	1,538	1,193
	430	438	400	285	257
	4,377	4,112	3,440	3,898	3,571
	49.0	42.2	42.9	43.6	39.2
	7.4	10.6	9.6	40.3	3.5
	725	593	274	387	229
	5,159	4,758	3,766	4,369	3,843
	10,373	9,802	7,552	7,400	7,749
	18,537	17,965	15,678	15,312	14,523
Assets — additional as-filed lines
	0.0	0.0	6.4	—	0.0
Trade payables — MSME split
	50.7	102	42.0	—	—
	2,684	2,378	1,492	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

PPLPHARMA₹230.78

Piramal Pharma Ltd.

· Pharma & Health

₹ CrorePeersDIVISLAB SYNGENE GLAND WOCKPHARMA ASTERDM COHANCE LALPATHLAB NATCOPHARMMcap ₹30,628 Cr

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Non-current Assets
+ Property, Plant & Equipment	3,363.0	3,872.6	4,176.0	4,450.7	4,496.1
+ Capital Work-in-Progress	852.9	565.7	489.1	799.2	965.9
+ Goodwill	1,107.5	1,122.6	1,148.2	1,257.4	1,405.3
+ Other Intangibles	2,772.6	2,617.1	2,450.9	2,583.9	2,848.3
+ Intangibles under Development	565.7	550.1	487.8	300.6	305.5
+ Investments (Equity Method)	170.1	205.3	226.8	244.2	109.6
+ Non-current Investments	41.8	34.9	44.3	60.8	62.7
+ Other Non-current Financial Assets	247.0	20.8	20.7	40.3	52.0
Non-current Financial Assets	288.8	55.8	65.0	101.1	114.6
+ Deferred Tax Assets	349.3	386.5	393.1	514.7	494.0
+ Other Non-current Assets	217.2	471.7	443.7	521.5	544.3
Total Non-current Assets	9,687.1	9,847.3	9,880.6	10,773.4	11,283.6
Current Assets
+ Inventories	1,681.4	2,175.9	2,312.7	3,064.4	3,294.8
+ Current Investments	427.1	144.7	19.6	131.8	261.4
+ Trade Receivables	1,799.3	2,134.4	2,349.5	2,157.7	2,253.7
+ Cash & Cash Equivalents	195.6	356.8	369.0	1,199.9	545.0
+ Other Bank Balances	112.0	125.7	132.5	23.8	23.6
+ Other Current Financial Assets	92.4	15.9	55.6	65.5	60.1
Current Financial Assets	2,626.4	2,777.6	2,926.1	3,578.6	3,143.8
+ Other Current Assets	527.7	511.0	551.8	548.7	815.0
Total Current Assets	4,835.5	5,464.5	5,797.0	7,191.7	7,253.7
Total Assets	14,522.6	15,311.8	15,677.6	17,965.0	18,537.2
Equity
+ Equity Share Capital	1,193.3	1,323.0	1,324.4	1,327.2	1,328.4
+ Other Equity / Reserves	5,580.2	6,588.4	6,801.1	6,835.5	6,813.9
Equity — Owners of Parent	6,773.5	7,911.4	8,125.5	8,162.6	8,142.2
+ Minority Interest	—	—	0.0	0.0	22.5
Total Equity	6,773.5	7,911.4	8,125.5	8,162.6	8,164.7
Liabilities
+ Borrowings — Non-current	3,383.5	2,483.8	3,214.1	4,300.0	4,453.6
+ Other Non-current Financial Liab	106.9	118.0	99.2	135.4	160.0
Non-current Financial Liabilities	3,490.4	2,601.7	3,313.2	4,435.4	4,613.6
+ Provisions — Non-current	20.7	32.3	48.7	94.3	117.0
+ Deferred Tax Liabilities	219.3	229.2	248.4	358.2	351.1
+ Other Non-current Liabilities	175.6	167.9	175.6	156.3	132.3
Non-current Liabilities	3,906.0	3,031.1	3,785.9	5,044.1	5,214.0
+ Borrowings — Current	2,121.2	2,075.1	1,506.2	1,195.5	1,211.7
+ Trade Payables	1,192.7	1,538.4	1,533.8	2,479.1	2,734.8
+ Other Current Financial Liab	257.4	284.6	400.0	437.7	430.1
Current Financial Liabilities	3,571.4	3,898.1	3,439.9	4,112.3	4,376.7
+ Provisions — Current	39.2	43.6	42.9	42.2	49.0
+ Current Tax Liabilities	3.5	40.3	9.6	10.6	7.4
+ Other Current Liabilities	228.9	387.4	273.9	593.2	725.4
Current Liabilities	3,843.1	4,369.3	3,766.3	4,758.3	5,158.5
Total Liabilities	7,749.1	7,400.4	7,552.1	9,802.4	10,372.5
Total Equity & Liabilities	14,522.6	15,311.8	15,677.6	17,965.0	18,537.2
Assets — additional as-filed lines
+ Current Tax Assets	0.0	—	6.4	0.0	0.0
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	—	42.0	101.6	50.7
+ Dues to Other Creditors — Current	—	—	1,491.8	2,377.5	2,684.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.